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CONCISE COMMUNICATIONS 
Mycobacterium kansasii septic arthritis in a patient 
with acquired immune deficiency syndrome 
Mycobacterium kansasii septic arthritis is rare, oc- 
curring mainly in joints with preexisting abnormalities or in 
an immunocompromised host (1,2). Infection may arise from 
hematogenous spread (i.e., from the lungs) or from local 
trauma, but some cases have no identifiable source. While 
M kansasii causes several infectious syndromes in patients 
with acquired immune deficiency syndrome (AIDS), 
M kansasii septic arthritis in an AIDS patient has not previ- 
ously been reported. We recently treated a patient infected 
with the human immunodeficiency virus (HIV) who developed 
a septic monarthritis of the elbow due to M kansasii. 
The patient was a 28-year-old HIV-positive man who 
was admitted to University of Michigan Hospital with pain 
and swelling of the right elbow (pain of 1 month's duration, 
swelling of 4 days' duration). He denied recent fever, cough, 
dyspnea, dysuria, penile discharge, ocular inflammation, 
skin eruption, or trauma to the right arm. Over the last year 
he had lost 40 pounds and had experienced chronic diarrhea, 
nausea, and night sweats. His HIV infection had been 
confirmed by enzyme-linked immunosorbent assay and by 
Western blot (HIV and p24 antigen). He had been treated for 
Entamoeba histolytica diarrhea, tinea cruris, tinea corporis, 
chronic oral candidiasis, and recurrent cutaneous herpes 
simplex. At admission, he was being treated with acyclovir, 
cimetidine, clotrimazole troches, cephalexin (taken for 48 
hours prior to admission without improvement), and penta- 
midine (monthly, by aerosol). 
His physical examination was notable for an asthenic 
appearance, but fever, skin lesions, and abnormal breath 
sounds were absent. His right elbow was warm, swollen, 
markedly tender, and held at 45" flexion, permitting only 5" 
of further motion. Findings of peripheral blood studies 
included leukopenia (3,500 white blood cells [WBC]/mm3 
with 64% polymorphonuclear cells, 19% bands, 10% lym- 
phocytes, 6% monocytes, and 1% eosinophils), absolute 
CD4+ lymphopenia (12 cells/mm3, with a CD4:CD8 ratio of 
0.03), and a rapid erythrocyte sedimentation rate (75 m d  
hour; Westergren method). Radiographic studies revealed 
normal findings in the chest and no abnormalities, other than 
soft tissue swelling, in the right elbow. Arthrocentesis 
yielded 12 cc of synovial fluid classified as type I1 (6,450 
WBC/mm3: 91% polymorphonuclear cells, 2% lymphocytes, 
7% histiocytes) that contained no crystals seen on polarized 
light microscopy and no organisms seen by Gram's, acid- 
fast, or KOH stains. 
Initial treatment with intravenous ceftazidime and 
vancomycin for presumed bacterial septic arthritis was 
changed on the sixteenth hospital day to isoniazid, rifampin, 
and ethambutol when acid-fast bacilli (nontuberculosis, pho- 
tochromogentlater identified as M kansasii-were identi- 
fied in cultures of the initial synovial fluid (and later from the 
subsequent arthrocenteses). Findings from urine culture 
were negative. His symptoms improved significantly after 2 
weeks of antimycobacterial treatment, and repeat radiogra- 
phy of the right elbow showed reduced soft tissue swelling. 
The patient moved to another state where he continued 
antituberculous therapy and noted resolution of the elbow 
symptoms; however, he contracted several opportunistic 
infections and died 9 months after the presentation with 
septic arthritis. 
M kansasii is a photochromogenic atypical mycobac- 
terium (Runyon group 1) that can occur as a disseminated 
process (3), but often appears as a local infection, affecting 
the lungs (4), genitourinary tract (9, skin (6), and bones, 
joints, or tendon sheaths (1). Predisposing factors for 
M kansasii infection are not well established, although many 
reported cases have involved an immunocompromised host. 
Hence, it is surprising that M kansasii septic arthritis in an 
AIDS patient had thus far not been reported. A recent 
history of local trauma (including arthrocentesis or joint 
injection) has frequently been associated with M kansasii 
septic arthritis and/or tenosynovitis. Preexisting joint dis- 
ease can serve as a predisposing factor in some cases, and 
may lead to delayed diagnosis when indolent progression of 
symptoms in a chronically abnormal joint is erroneously 
ascribed to progression of underlying joint disease. How- 
ever, in a number of reported cases, there was no apparent 
predisposing condition. 
Septic monarthritis and tenosynovitis are observed 
most often, though polyarthritis and osteomyelitis have also 
been reported (1,2). The outcome of M kansasii septic 
arthritis is variable, possibly related in part to the presence 
or absence of underlying rheumatic disease or alterations in 
immune function. The majority of previously healthy pa- 
tients recover fully; bone and joint destruction are more 
commonly observed in patients with underlying disease. 
Medical therapy-consisting of combination chemotherapy 
with isoniazid, rifampin, and at least one additional anti- 
tuberculous agent-is usually effective, although surgical de- 
bridement of infected tissue is required in cases in which there 
is lack of response to a trial of pharmacologic therapy. Re- 
sponse to chemotherapy is often good despite in vitro resis- 
tance of the organism to one or more of the agents used (1,2). 
Mycobacterial disease is an important cause of mor- 
bidity and mortality in patients with HIV infection (7). 
Disease due to Mycobacterium tuberculosis may occur at 
any stage of AIDS (7). Mycobacterium avium complex 
infection is the most common nontuberculous mycobacterial 
pathogen in AIDS patients, and is well recognized as a 
late-stage, poorly responsive manifestation. M kansasii is 
the second most common nontuberculous pathogen in AIDS 
and usually occurs as a pulmonary process, which generally 
responds well to antituberculous chemotherapy (8). Re- 
ported M kansusii bone and joint involvement in AIDS 
patients has been limited to 2 case reports of osteomyelitis 
(9,lO) and 1 case of osteomyelitis mentioned in a report of a 
record review of a series of AIDS patients with M kansasii 
infection in AIDS (8). In fact, only 2 cases of septic arthritis 
due to mycobacteria in HIV-infected patients have been 
reported, both involving M auium complex (1 1,12). 
Septic arthritis is less common than many of the 
other musculoskeletal syndromes reported to occur in HIV- 
infected patients (13). Although an occasional report has 
suggested that septic arthritis in an AIDS patient may 
present in an occult manner and follow an indolent course 
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(14), more recent reports suggest that the responsible organ- 
isms and clinical course of septic arthritis in AIDS patients 
are quite similar to those features in patients not infected 
with HIV (10). 
The diagnosis of M kansasii infection should be 
considered in all cases of indolent arthritis, in exacerbations 
of chronic arthritis, and in cases of acute or indolent arthritis 
in immunosuppressed patients, including those whose immu- 
nosuppression is due to infection with HIV. This is the first 
reported case of M kansasii septic arthritis in a patient with 
AIDS, and it seems likely that more will follow. As with 
other organ systems in patients with AIDS, joint infection 
due to M kansasii seems to respond well to antituberculous 
chemotherapy. 
Alan W. Friedman, MD 
Robert W. Ike, MD 
University of Michigan Multipurpose Arthritis Center 
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Sterile oily abscess from depot gold therapy 
Two men of asthenic habitus with seropositive rheu- 
matoid disease requested that their gold injection (aurothio- 
glucose [ATG] in sesame oil; Solganal; Schering, Kenil- 
worth, NJ) be given in the arm. After complete response, 
each patient opted for no maintenance injections, and sub- 
sequently, they experienced a relapse of symptoms. 
During the third course of ATG treatment, at a 
cumulative dose of 10,125 mg, the ATG was stopped in 
patient 1 because of a lack of response. Five months after the 
injections were stopped, the patient experienced pain, 
warmth, and swelling in the deltoid region. Similar symp- 
toms developed in patient 2, who had an incomplete re- 
sponse during the second course of treatment, at a cumula- 
tive dose of 10,345 mg of ATG. 
Surgical exploration of the deltoid region in each 
patient demonstrated a sterile abscess, with oily yellow- 
brown material. Histologic features of the skeletal muscle 
were similar: walls of a thick layer of histiocytes, including 
giant cells, interrupted by various-sized vacuoles; golden- 
brown pigment. Polarizing light microscopy demonstrated 
numerous doubly refractile bodies. 
To determine whether there were adverse effects of 
ATG at the recommended intragluteal injection sites, 7 
consecutive patients on long-term regimens of ATG injec- 
tions were screened using ultrasound. None of these patients 
had symptoms or palpable changes. Ultrasound defects were 
identified in the 2 patients who had received virtually all ATG 
injections on one side. One patient (cumulative dose 9,035 mg 
of ATG) had 2 hypoechoic areas, measuring 1.3 cm and 2.4 x 
1.3 cm; the other patient (10,300 mg of ATG) had several 
hypoechoic areas, measuring (1 cm each. No defined hypo- 
echoic areas were noted in the 5 patients who had received 
their injections on alternate sides (cumulative doses 5,410, 
9,230, 10,730, 11,340, and 17,055 mg of ATG, respectively). 
Sesame oil-based ATG has long been the only for- 
mulation available. Its benefits are a rarity of vasomotor 
nitritoid reactions, even with high doses, and longer inter- 
vals between injections once response is achieved (1). A 
computer literature search to 1966 yielded no reports of 
sterile abscesses from injections of ATG in oil. Comroe had 
stated that “a short period of massage . . . will usually 
prevent the formation of hard nodules . . .” (2) at the 
injection site. Sterile abscesses were rarely seen (Hollander 
JL: personal communication). 
In a relevant study of 109 psychiatric patients who 
were receiving depot neuroleptics (3), 4 patients had symp- 
tomatic oily abscesses which required surgical drainage. 
These patients were receiving perphenazine enanthate in 
sesame oil, in a large volume (8-11 ml once weekly). No 
lesions were palpable in patients who were receiving smaller 
volumes less frequently. 
Initial trials of oil adjuvant influenza vaccine demon- 
strated a high rate of sterile abscesses (4). Subsequent 
studies in monkeys showed that oil globules, granulomas, 
and giant cells were present at the injection site of any 
preparation containing oil. The breast muscle of a 21-day-old 
chicken was shown to contain fat globules, but no tissue 
reaction was seen. 
In studies of pigs given injections of an antibiotic in 
